Key opinion leaders review clinical cases in thyroid cancer, focusing on recent advances, treatment options, and clinical trials impacting clinical practice.
September 28th 2021
Andrew Gianoukakis, MD, reviews the case of a 71-year-old woman with RAI-refractory differentiated thyroid cancer and the panel discuss relevant clinical trial data.
Experts in thyroid cancer discuss treatment considerations surrounding the use of radioiodine therapy in patients with thyroid cancer.
Andrew Gianoukakis, MD, reviews the treatment and management options for a 71-year-old woman with RAI- refractory differentiated thyroid cancer.
The panel of experts share their insights into the definition and clinical presentation of radioiodine-refractory DTC.
Experts in the management of thyroid cancer discuss radioactive iodine therapy and the clinical implications of mutational status in RAI- refractory DTC.
Marcia Brose, MD and Lori Wirth, MD, discuss molecular testing considerations in patients with radioiodine-refractory DTC.
Dr Andrew Gianoukakis, explores considerations surrounding systemic therapy in patients with RAI-refractory differentiated thyroid cancer.
Andrew Gianoukakis, MD, reviews the NCCN guidelines for the treatment of patients with thyroid cancer.
Dr Andrew Gianoukakis reviews the study design and key efficacy data of the phase 3 DECISION and SELECT trials.
September 30th 2021
Andrew Gianoukakis, MD, and Lori Wirth, MD, examine post-hoc analysis data from the phase 3 SELECT trial.